All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
Multiple Myeloma Hub Symposium 2024: How to sequence BCMA-directed therapies in early RRMM
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium titled: How to sequence B-cell maturation antigen (BCMA)-directed therapies in early relapsed/refractory multiple myeloma (RRMM). During the symposium, Martin Kaiser, The Royal Marsden Hospital, London, UK, delivered a presentation on BCMA-directed antibody–drug conjugates (ADCs) for the treatment of MM.
In this presentation, Professor Kaiser focuses on the potential and evolving role of ADCs in the treatment of multiple myeloma, particularly in comparison to other BCMA-targeting therapies such as bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies. The discussion includes mechanisms of action (Figure 1), recent clinical trial data, toxicity profiles, resistance mechanisms (Figure 2), and future directions for optimizing ADC use. The efficacy of belantamab mafodotin in triplet regimens and its potential role in therapy sequencing are also covered.
Figure 1. BCMA-directed ADCs: Mechanism of action*
ADC, antibody–drug conjugate; BCMA, B-cell maturation antigen; DNA, deoxyribonucleic acid.
*Khattak et al.1
Figure 2. Impact of ADCs on mechanisms of resistance: T-cell independence*
ADC, antibody–drug conjugate; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor.
*Su and Ye.2
This independent educational activity was supported by GSK. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.
Multiple Myeloma Hub Symposium 2024: How to sequence BCMA-directed therapies in early RRMM
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox